Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarter: Boston, MA; NASDAQ:SYRS), based on mutual agreement. The acquisition was completed on February 26, 2025.

Tamibarotene is a retinoic acid receptor agonist, and Rege Nephro is currently conducting a Phase 2 clinical trial in Japan for Tamibarotene (RN-014) targeting ADPKD (autosomal dominant polycystic kidney disease). Syros Pharmaceuticals was carrying out a Phase 3 clinical trial of Tamibarotene for indications including MDS (myelodysplastic syndrome) and AML (acute myeloid leukemia).

This acquisition will accelerate our future global clinical developments of RN-014.

Media Inquiries:
Katsuhisa Yamaguchi, CFO
Rege Nephro Co., Ltd.
TEL: 075-744-6858
E-mail: info@regenephro.co.jp